Current recommendations on first line therapy of CLL. FCR indicates fludarabine, cyclophosphamide, rituximab; AlloSCT, allogeneic stem cell transplantation; CLB, chlorambucil; Al, alemtuzumab; HD, high dose; R, rituximab; O, ofatumumab; P53mut, mutation of the p53 gene; and del(17p), deletion of the short arm of chromosome 17.